NewEdge Advisors LLC Sells 1,630 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NewEdge Advisors LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 36.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,800 shares of the biopharmaceutical company's stock after selling 1,630 shares during the period. NewEdge Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $1,994,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after buying an additional 9,381 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after acquiring an additional 149,124 shares during the period. Loomis Sayles & Co. L P increased its holdings in shares of Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after acquiring an additional 393,997 shares during the period. Finally, Amundi increased its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.4 %

Regeneron Pharmaceuticals stock traded up $8.22 during mid-day trading on Monday, reaching $610.86. The stock had a trading volume of 1,175,211 shares, compared to its average volume of 726,457. The company has a market capitalization of $66.78 billion, a price-to-earnings ratio of 15.96, a PEG ratio of 2.34 and a beta of 0.44. The company has a 50-day moving average price of $635.89 and a two-hundred day moving average price of $719.08. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.86 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on REGN. Citigroup cut their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Finally, Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $945.32.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.